ABL1 BCR::ABL Q252H (Q29938514)

genetic variant

Q252H
RS121913458
Q271H
BCR-ABL Q252H
BCR-ABL Q271H
BCR-ABL1 Q252H
BCR-ABL1 GLN252HIS
BCR::ABL Q252H

Language	Label	Description	Also known as
English	ABL1 BCR::ABL Q252H	genetic variant	Q252H RS121913458 Q271H BCR-ABL Q252H BCR-ABL Q271H BCR-ABL1 Q252H BCR-ABL1 GLN252HIS BCR::ABL Q252H

Statements

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

chromosome

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

genomic start

133738356

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

genomic end

133738356

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

positive therapeutic predictor for

imatinib

medical condition treated

chronic myeloid leukemia

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2650

stated in

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

negative therapeutic predictor for

dasatinib monohydrate

determination method

CIViC evidence level C

rating

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4327

stated in

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

dasatinib monohydrate

determination method

CIViC evidence level D

rating

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6219

stated in

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

imatinib mesylate

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6245

stated in

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

dasatinib monohydrate

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6274

stated in

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

axitinib

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4323

stated in

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

imatinib

determination method

CIViC evidence level C

rating

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2651

stated in

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

dasatinib monohydrate

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

medical condition treated

cancer

statement disputed by

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2653

stated in

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

nilotinib

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

medical condition treated

cancer

statement disputed by

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2653

stated in

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

Identifiers

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

dbSNP Reference SNP number

1 reference

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

NP_005148.2:p.Gln252His

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

NC_000009.11:g.133738356G>C

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

ENST00000318560.5:c.756G>C

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1024

ABL1 BCR::ABL Q252H (Q29938514)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

ABL1 BCR::ABL Q252H (Q29938514)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search